stockrow
Saturday 7 November 2026
Export STLN’s income statement to Excel — free account
Starling Oncology, Inc.
STLN Healthcare Medical Care Facilities
Starling Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.7 million, up 27.8% from fiscal 2024.
- Revenue
- +24.3%
- EPS
- +7.14%
- Free cash flow
- +167.1%
- Total debt
- −4.82%
Quarter to September 2026, against a year earlier
3.51
3.19
−47.61%
Follow STLN
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | 188 | 203 | 252 | 324 | 393 | 503 | 620 | +21.8% | 665 | 884 | 1,140 | +31.4% | |
| Gross margin, % | — | — | — | — | 19.67 | 20.12 | 20.63 | 18.37 | 13.73 | 15.20 | 0.00 | (4.5) pt | ||||||
| EBT | — | — | — | 0 | (15) | (12) | 0 | (83) | (65) | (61) | (36) | +445.7% | ||||||
| EBT margin, % | — | — | — | 0.00 | (7.90) | (5.71) | (0.04) | (25.63) | (16.44) | (12.08) | (5.73) | (12.1) pt | ||||||
| Net income | — | 0 | — | 0 | (14) | (11) | 0 | (83) | (65) | (61) | (36) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 3.17 | 3.07 | 3.47 | 4.40 | 5.24 | 5.44 | 5.92 | n/m | |||||
| Earnings | — | — | — | 0.00 | (0.24) | (0.16) | 0.00 | (0.92) | (0.71) | (0.54) | (0.29) | +220.3% | ||||||
| Cash flow | — | — | — | 0.00 | 0.01 | (0.49) | (0.85) | (0.49) | (0.35) | (0.27) | 0.22 | n/m | ||||||
| Capex | — | — | — | 0.00 | (0.02) | (0.05) | (0.08) | (0.06) | (0.05) | (0.03) | (0.04) | n/m | ||||||
| Free cash flow | — | — | — | 0.00 | (0.01) | (0.54) | (0.92) | (0.55) | (0.40) | (0.30) | 0.18 | n/m | ||||||
| Book value | — | — | — | 0.00 | 0.48 | 1.57 | 1.69 | 0.77 | 0.05 | (0.17) | (0.36) | n/m | ||||||
| Shares, m | — | — | — | 5 | 59 | 66 | 73 | 74 | 75 | 92 | 100 | +62.6% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | 0.00 | 3.18 | 0.46 | 0.52 | 0.06 | 0.65 | 0.59 | 0.8 | ||||||
| P/B | — | — | — | — | 22.72 | 6.20 | 0.95 | 2.97 | 6.48 | 0.00 | 0.00 | 6.6 | ||||||
| EV/Sales | — | — | — | — | 0.00 | 2.65 | 0.49 | 0.54 | 0.17 | 0.74 | 0.65 | 0.8 | ||||||
| EV/FCF | — | — | — | — | 1,268.51 | (15.12) | (1.85) | (4.25) | (2.21) | (13.42) | 21.43 | 205.3 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | 1 | (33) | (62) | (36) | (27) | (25) | 23 | n/m | |||||
| Capex | — | — | — | — | (1) | (3) | (6) | (5) | (4) | (3) | (4) | +21.8% | ||||||
| Free cash flow | — | — | — | — | (1) | (36) | (67) | (41) | (30) | (28) | 19 | +109.7% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | 0 | 1 | 124 | 101 | 109 | 60 | 42 | 14 | n/m | |||||
| Net debt | — | — | — | 0 | 6 | (115) | 7 | 4 | 43 | 44 | 36 | n/m | ||||||
| Shareholders’ equity | — | — | — | 0 | 28 | 104 | 123 | 57 | 4 | (16) | (37) | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | (9.20) | (43.57) | (8.12) | 0.07 | (35.28) | (33.86) | (35.93) | (20.23) | (26.7) pt | |||||
| ROIC | — | — | — | 0.00 | (15.05) | 0.00 | (39.40) | (78.92) | (79.86) | (80.21) | 0.00 | (80.2) pt | ||||||
| ROE | — | — | — | (0.02) | (101.85) | (16.52) | 0.13 | (92.20) | (213.36) | 999.19 | 143.21 | +999.2 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | 3 | 3 | 658 | 750 | 800 | 825 | 641 | — | +144.5% | |||||
| Revenue/emp, $m | — | — | — | 0.00 | 62.51 | 0.31 | 0.34 | 0.41 | 0.48 | 0.78 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 6 Nov 2026
Starling Oncology, Inc. vs peers in Medical Care Facilities (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NUTX Nutex Health Inc. | $1.3B | 6.9× | 7.3× | −13.62% (below 0%: shrinking) | n/m | +19.44% (above 0%: growing) | 67.04% | 57.75% | Compare |
| INNV InnovAge Holding Corp. | $1.2B | 124× | 20.9× | +12.14% (above 0%: growing) | +155.00% (above 0%: growing) | +622.82% (above 0%: growing) | 24.02% | 7.61% | Compare |
| CMPS COMPASS Pathways PLC Sponsored ADR | $1.1B | — (loss-making) | — | — | n/m | −44.62% (below 0%: shrinking) | — | 0.00% | Compare |
| GMRS GMR Solutions Inc. | $675.8M | 15.8× | — | — | n/m | — | 100.00% | 3.80% | Compare |
| STLN Starling Oncology, Inc. | $669.9M | — (loss-making) | — (loss-making) | +24.31% (above 0%: growing) | n/m | +167.10% (above 0%: growing) | 0.00% | (1.76%) | |
| MCTA Charming Medical Limited | $497.3M | — | — | — | — | — | — | — | Compare |
| SRTA Strata Critical Medical, Inc. | $469.8M | — (loss-making) | — (loss-making) | +50.27% (above 0%: growing) | n/m | +121.34% (above 0%: growing) | 22.70% | (5.17%) | Compare |
| AUNA Auna S.A. | $339.7M | 66.7× | 6.1× | +20.51% (above 0%: growing) | −61.29% (below 0%: shrinking) | +121.08% (above 0%: growing) | 35.72% | 13.09% | Compare |
| CYH Community Health Systems, Inc. | $321.5M | 4.2× | — (loss-making) | −10.69% (below 0%: shrinking) | n/m | +857.14% (above 0%: growing) | 85.24% | 5.30% | Compare |
| Median of peers | $586.5M | 15.8× | 7.3× | +12.14% | — | +121.21% | 51.38% | 5.30% |
Pay and ownership Proxy statement filed 30 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 1.93m | 7.96m | 174.51 |
| 2024 | 1.12m | (510.55k) | 15.15 |
Ownership
Directors and executive officers, together
4.40%
Jorey Chernett
10.50%
Parian Global TOI LP
8.90%
M33 Growth I L.P.
6.70%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement